- Home
- WLYB vs IMCR Comparison
WLYB vs IMCR Comparison
Compare WLYB & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLYB
- IMCR
- Stock Information
- Founded
- WLYB 1807
- IMCR 2008
- Country
- WLYB United States
- IMCR United Kingdom
- Employees
- WLYB N/A
- IMCR N/A
- Industry
- WLYB Books
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WLYB Consumer Discretionary
- IMCR Health Care
- Exchange
- WLYB Nasdaq
- IMCR Nasdaq
- Market Cap
- WLYB 2.1B
- IMCR 1.8B
- IPO Year
- WLYB N/A
- IMCR 2021
- Fundamental
- Price
- WLYB $39.85
- IMCR $37.20
- Analyst Decision
- WLYB
- IMCR Buy
- Analyst Count
- WLYB 0
- IMCR 9
- Target Price
- WLYB N/A
- IMCR $57.00
- AVG Volume (30 Days)
- WLYB 177.0
- IMCR 316.1K
- Earning Date
- WLYB 09-04-2025
- IMCR 11-05-2025
- Dividend Yield
- WLYB 3.63%
- IMCR N/A
- EPS Growth
- WLYB N/A
- IMCR N/A
- EPS
- WLYB 1.78
- IMCR N/A
- Revenue
- WLYB $1,670,600,000.00
- IMCR $356,145,000.00
- Revenue This Year
- WLYB $1.45
- IMCR $31.83
- Revenue Next Year
- WLYB $2.70
- IMCR $8.50
- P/E Ratio
- WLYB $21.75
- IMCR N/A
- Revenue Growth
- WLYB N/A
- IMCR 26.78
- 52 Week Low
- WLYB $37.27
- IMCR $23.15
- 52 Week High
- WLYB $52.90
- IMCR $39.33
- Technical
- Relative Strength Index (RSI)
- WLYB 39.69
- IMCR 76.55
- Support Level
- WLYB $39.63
- IMCR $31.85
- Resistance Level
- WLYB $42.70
- IMCR $33.08
- Average True Range (ATR)
- WLYB 0.02
- IMCR 1.28
- MACD
- WLYB 0.09
- IMCR 0.50
- Stochastic Oscillator
- WLYB 70.97
- IMCR 100.00
About WLYB John Wiley & Sons Inc.
John Wiley & Sons Inc is one of the world's greatest publishers and a trusted leader in research and learning. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.